PS04-01 **Clinical impact of timing of systemic therapy in patients with early triple negative breast cancer.** Maria Eleni Hatzipanagiotou (1)  Miriam Pigerl (2)  Michael Gerken (3)  Sophie Räpple (2)  Verena Zeltner (2)  Madeleine Hetterich (2)  Elisabeth C. Inwald (2)  Monika Klinkhammer-Schalke (4)  Olaf Ortmann (2)  Stephan Seitz (2)
(1) Department of Gynecology and Obstetrics, University Medical Centre Regensburg, Bayern, Germany; (2) Department of Gynecology and Obstetrics, University Medical Centre Regensburg, Germany; (3) Bavarian Cancer Registry, Regional Centre Regensburg, Bavarian Health and Food Safety Authority; (4) Tumor Center Regensburg - Centre for Quality Management and Health Services Research, University of Regensburg.

PS04-02 **BRCA testing and PARP inhibitor utilization in real-world HER2-negative metastatic breast cancer.** Siddhartha Yadav (1)  Sam Hillman (2)  Linlin Luo (3)  Weiyan Li (3)  Jagadeswara Earla (4)  Xiaoqing Xu (5)
(1) Mayo Clinic, Rochester, Minnesota, United States; (2) AstraZeneca, United Kingdom; (3) AstraZeneca, Gaithersburg, MD, United States; (4) Merck & Co., Inc., Rahway, NJ, United States; (5) AstraZeneca.

PS04-03 **Survival benefit of regional nodal irradiation in clinically node-positive breast cancer following neoadjuvant chemotherapy and breast-conserving surgery.** Mahtab Vasigh (1)  Richard Bleicher (2)  Austin Williams (3)  Allison Aggon (2)  Mary Pronovost (4)  Andrea Porpiglia (2)  Matthew Pierotti (3)  Christian Cruz Pico (3)
(1) Department of surgical Oncology, Fox Chase Cancer Center, Baltimore, Maryland, United States; (2) Fox Chase Cancer Center, Philadelphia, PA, United States; (3) Department of surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, United States; (4) Temple University, Philadelphia, PA, United States.

PS04-04 **Adverse effects (AEs) reported via Patient Reported Outcome Measures (PROMs): A longitudinal analysis of the IMPORT HIGH breast radiotherapy trial (CRUK/06/003).** Sze Yi Ng (1)  Indrani Bhattacharya (2)  Joanne Haviland (3)  Clare Griffin (1)  Mark Sydenham (4)  Anna Kirby (5)  Penelope Hopwood (6)  Cliona Kirwan (7)  Charlotte Coles (8)  Judith Bliss (4)
(1) Clinical Trials and Statistics Unit, Institute of Cancer Research, London, England, United Kingdom; (2) Cambridge University Hospitals NHS Foundation Trust; (3) Queen Mary University of London, United Kingdom; (4) Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, England, United Kingdom; (5) The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust; (6) Clinical Trials and Statistics Unit, Institute of Cancer Research, London, England, United States; (7) The University of Manchester; (8) University of Cambridge, United Kingdom.

PS04-06 **Breast cancer recurrence among women with pre-diagnostic major depression and co-existing substance abuse disorder: A retrospective study in the United States Veterans Health Administration Cohort.** Maya Aboumrad (1)  Kala Visvanathan (2)
(1) Johns Hopkins Bloomberg School of Public Health, MD and White River Junction VA Medical Center, Baltimore, Maryland, United States; (2) Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, MD and Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.
PS04-07 Associations between Virtual Care Access and Psychological and Mental Health Conditions among Adults with Breast Cancer in the US: A Population-Based Analysis. Jincong Freeman (1)  Ted Akhiwu (2)  Yong Gun Lee (3)  Xinyi Li (4)
(1) University of Chicago, Chicago, Illinois, United States;(2) Department of Medicine, MedStar Union Memorial Hospital, Baltimore, MD, United States;(3) Rutgers, The State University of New Jersey, New Brunswick, NJ, United States;(4) Milken Institute School of Public Health, The George Washington University, Washington, District of Columbia, United States.

(1) Columbia University, New York, NY, United States;(2) Fred Hutchinson Cancer Research Institute;(3) SWOG Statistics and Data Management Center, Seattle, WA, United States;(4) ASCO;(5) Herbert Irving Comprehensive Cancer Center, Vagelos College of Physicians and Surgeons, Columbia University;(6) University of Michigan Medical School;(7) Fred Hutchinson Cancer Center.

PS04-09 Patient-Reported Benefit of Resources Designed to Assist with the Financial Toxicity of Breast Cancer. Fumiko Chino (1)  Sam Meske (2)  Muath Giaddui (3)  Donna-Marie Manasseh (4)  Bridgette Thom (5)  Marisa Weiss (2)
(1) Memorial Sloan Kettering Cancer Center, New York, NY, United States;(2) Breastcancer.org;(3) Lankenau Institute for Medical Research;(4) Maimonides Medical Center;(5) UNC Lineberger Comprehensive Cancer Center.

PS05-01 Accuracy and safety of fibroblast activation protein inhibitor (FAPI) PET/CT in diagnosis of axillary lymph node metastasis in early breast cancer patients: a prospective cohort study (PFB-01&02 study). Bo Pan (1)  Zhixin Hao (1)  Chao Ren (1)  Lifan Zhang (1)  Yidong Zhou (1)  Qiang Sun (1)  Li Huo (1)
(1) Peking Union Medical College Hospital.

PS05-02 PET Imaging of PARP Expression as a Biomarker of Response to Chemotherapy in Breast Cancer: A Nonrandomized Clinical Trial. Sarah Gitto (1)  Anthony Young (2)  Ira Bleiweiss (2)  Amy Clark (2)  Elizabeth McDonald (2)

(1) Department of Surgery, School of Clinical Sciences at Monash Health, Monash University, Victoria, Australia;(2) Breast Center, Lake Macquarie Private Hospital, New South Wales, Australia;(3) Austin Health;(4) Royal Brisbane Hospital, Queensland, Australia;(5) Monash Health;(6) Monash Medical Center, Victoria, Australia;(7) Imagion Biosystems Inc.;(8) Imagion Biosystems Ltd;(9) Imagion Biosystems Inc, San Diego, California, United States.

PS05-04 [89Zr]Trastuzumab-PET/MRI to Characterize HER2+ Breast Cancer: A Quantitative Approach on Tumor Heterogeneity. Ameer Mansur (1)  Moozhan Nikpanah (1)  Johnathan McConathy (1)  Erica
PS05-06 Outcomes of Surveillance using Contrast Enhanced Mammography in Women with a Personal History of Breast Cancer. Julia Matheson (1) Carolyn Nickson (2) Kenneth Elder (3) Allan Park (3) Allison Rose (4) Bruce Mann (5)
(1) Department of Surgery, Royal Melbourne Hospital and the University of Melbourne, Parkville, Victoria, Australia;(2) Daffodil Centre, The University of Sydney, a joint venture with Cancer Council New South Wales. Melbourne School of Population and Global Health, The University of Melbourne, Australia;(3) Royal Melbourne Hospital, Melbourne, VIC, Australia;(4) RMH;(5) The Royal Melbourne Hospital, Parkville, Victoria, Australia.

(1) The University of Texas MD Anderson Cancer Center, Houston, TX, United States;(2) University of Texas MD Anderson Cancer Center, Houston, TX, United States;(3) MD Anderson Cancer Center, TX, United States;(4) UT MD Anderson Cancer Center;(5) University of Texas MD Anderson Cancer Center;(6) MD Anderson Cancer Center, Houston, TX, United States;(7) UT MD Anderson Cancer Center, Houston, TX, United States;(8) Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, United States;(9) Breast Medical Oncology Department, The University of Texas MD Anderson Cancer Center.

PS05-08 Restriction Spectrum Imaging MRI for automated evaluation of response to neoadjuvant therapy in breast cancer. Maren Marie Sjaastad Andreassen (1) Stephane Loubrie (2) Michelle Tong (2) Lauren Fang (2) Tyler Seibert (3) Anne Wallace (4) Somaye Zare (5) Haydee Ojeda-Fournier (2) Joshua Kuperman (2) Michael Hahn (2) Neil Jerome (6) Tone Batthen (6) Ana Rodriguez-Soto (2) Anders Dale (2) Rebecca Rakow-Penner (2)
(1) Department of Research and Innovation, Vestre Viken, Norway;(2) Department of Radiology, University of California, San Diego, La Jolla, CA, United States;(3) Department of Radiation Medicine and Applied Sciences, University of California, San Diego, La Jolla, CA, United States;(4) University of California San Diego, San Diego, CA, United States;(5) School of Medicine, University of California, San Diego, La Jolla, CA, United States;(6) Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Norway.

PS05-09 A single-arm Phase II clinical study of fulvestrant combined with chemotherapy in the neoadjuvant treatment of HR+/HER2- locally advanced breast cancer. Qing Shao (1) Jing Wu (1) Ningning Zhang (1) Xiaohua Zeng (1)
(1) Chongqing University Cancer Hospital.

(1) Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;(2) The Royal Marsden Hospital, United Kingdom;(3) UT Southwestern Medical Center, Simmons Comprehensive Cancer Center, Dallas, TX, United States;(4) Legorreta Cancer Center at Brown University, Lifespan Cancer Institute, Providence, RI, United States;(5) Memorial Sloan Cancer Center, New York, NY, United States;(6) Mayo Clinic, Rochester, Minnesota, United States;(7) Laboratory for Translation Breast Cancer Research/KU Leuven, Leuven, Vlaams-Brabant, Belgium;(8) AstraZeneca, Gaithersburg, MD, United States;(9) Department of Pathology, Tohoku University Hospital, Japan.;(10) Eli Lilly and Company, Indianapolis, IN, United States;(11) Royal Marsden Hospital, Institute of Cancer Research, London, England, United Kingdom.


(1) Yale School of Medicine, Cancer Center, New Haven, CT, United States;(2) Natera, San Carlos, CA, United States;(3) Division of Hematology & Medical Oncology, Knight Cancer Institute, Oregon Health & Science University;(4) University of New Mexico Cancer Center, Albuquerque, NM, United States;(5) Cedars-Sinai;(6) Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute;(7) Swedish Medical Center, WA, United States;(8) University of Arizona Cancer Center, AZ, United States;(9) Oklahoma University of health Sciences, Oklahoma City, OK, United States;(10) Stony Brook Cancer Center;(11) Emory University School of Medicine, Atlanta, GA, United States;(12) LSUHSC, New Orleans;(13) The Ohio State University Comprehensive Cancer Center;(14) University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, United States;(15) DEPARTMENT OF MEDICINE University of Wisconsin School of Medicine and Public Health, Madison, WI, United States;(16) Criterium;(17) Pfizer Inc, San Francisco, CA, United States;(18) Natera;(19) University of Colorado Denver, Aurora, CO, United States.


(1) Washington University in St. Louis, St. Louis, MO, United States;(2) Department of Medicine, University of Udine;(3) Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy;(4) Massachusetts General Hospital Cancer Center / Dana Farber Cancer Institute;(5) Washington University in St Louis School of Medicine;(6) St. Luke’s Cancer Institute;(7) Washington University in St. Louis;(8) Cleveland Clinic;(9) Northwestern University - Feinberg School of Medicine;(10) Weill Cornell Medicine;(11) Department of Medicine, Division of Hematology-Oncology,
PS06-04 The prognostic and predictive impact of circulating tumour DNA (ctDNA) dynamics in patients with metastatic Triple Negative Breast Cancer (TNBC) on olaparib based therapy: Results from Cohort E of the PlasmaMATCH trial. Iseult Browne (1) Javier Pascual (2) Rosalind Cutts (3) Belinda Kingston (3) Sarah Hrebien (3) Lucy Kilburn (4) Alex Pearson (5) Laura Moretti (6) Andrew Wardley (7) Iain Macpherson (8) Richard Baird (9) Rebecca Roylance (10) Iris Faull (11) Kimberly C Banks (11) Isaac Garcia-Murillas (12) Judith Bliss (4) Alistair Ring (13) Nicholas Turner (14)

(1) Department Gynecology and Obstetrics, University of Ulm, Ulm, Baden-Württemberg, Germany; (2) Department of Obstetrics and Gynecology, University Hospital Ulm, Germany; (3) Department of Obstetrics and Gynecology, University Hospital Erlangen, Germany; (4) Women’s Clinic, University Clinics Tuebingen, Germany; (5) Onkologie Bethanien Frankfurt am Main, Germany; (6) Gemeinschaftspraxis Braunschweig, Germany; (7) Department of Gynecologic Oncology, Schwerpunktpraxis für Gynäkologische Onkologie, Germany; (8) Charité - Universitätsmedizin Berlin, Germany; (9) University Hospital Düsseldorf, Germany; (10) Universitätsklinikum Hamburg-Eppendorf, Germany; (11) National Center for Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Germany; (12) Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander-University of Erlangen-Nuremberg, Germany; (13) Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich-Alexander-University Erlangen-Nürnberg, Germany; (14) University of Munich, Germany; (15) Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Germany; (16) Guardant Health, Inc., Palo Alto, CA, United States.

(1) Dana Farber Cancer Institute; Harvard Medical School, Boston, MA, United States; (2) Department of Medical Oncology, Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, United States; (3) Precede Biosciences; (4) Dana-Farber Cancer Institute; (5) Breast Oncology Program, Dana-Farber Cancer Institute; Harvard Medical School, Boston, MA, United States; (6) Dana Farber Cancer Institute; (7) Precede biosciences; (8) Dana-Farber Cancer Institute, Boston, MA, United States; (9) Dana-Farber Cancer Institute, and Harvard Medical School, Boston, MA, United States.


(1) Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada; (2) UHN - University Health Network - Princess Margaret Cancer Centre; (3) University Health Network; (4) Princess Margaret Cancer Centre, Toronto, Ontario, Canada; (5) Saint Mary’s Hospital, McGill University, Montreal, QC, Canada; (6) Cancer Genomics Program; (7) Invitac Inc.; (8) NeoGenomics; (9) Bradfield Centre, Cambridge Science Park; (10) University Health Network, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada; (11) Princess Margaret Cancer Centre/UHN, toronto, Ontario, Canada.


(1) University of Wisconsin, Madison, Madison, WI, United States; (2) DEPARTMENT OF MEDICINE University of Wisconsin School of Medicine and Public Health, Madison, WI, United States; (3) University of Rochester Medical Center, Rochester, NY, United States; (4) University of Wisconsin Carbone Cancer Center, Madison, WI, United States; (5) University of Wisconsin, Madison, Madison, Wisconsin, United States.